Cefotaxime in the treatment of pneumococcal pneumonia
- 1 January 1980
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 6 (suppl A) , 177-180
- https://doi.org/10.1093/jac/6.suppl_a.177
Abstract
Cefotaxime, 1000 mg intramuscularly twice daily, was compared with cefazolin sodium, 500 mg intramuscularly twice daily, in the treatment of 28 patients with uncomplicated pneumococcal pneumonia. Patients were randomly assigned to therapy with one-third being treated with cefazolin sodium and two-thirds being treated with cefotaxime. No patients experienced side-effects or allergic reactions after receiving cefotaxime. All patients admitted into the study recovered satisfactorily without relapses. Cefotaxime is safe and effective in the previously described dosage for the treatment of pneumococcal pneumonia.Keywords
This publication has 0 references indexed in Scilit: